Symbol="MRSN"
AssetType="Common Stock"
Name="Mersana Therapeutics Inc"
Description="Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of Antibody Drug Conjugates (ADCs) for cancer patients with unmet needs. The company is headquartered in Cambridge, Massachusetts."
CIK="1442836"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="840 MEMORIAL DRIVE, CAMBRIDGE, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="148224000"
EBITDA="-218628992"
PERatio="None"
PEGRatio="0"
BookValue="0.745"
DividendPerShare="0"
DividendYield="0"
EPS="-2.13"
RevenuePerShareTTM="0.367"
ProfitMargin="0"
OperatingMarginTTM="-5.68"
ReturnOnAssetsTTM="-0.488"
ReturnOnEquityTTM="-1.923"
RevenueTTM="38717000"
GrossProfitTTM="-146804000"
DilutedEPSTTM="-2.13"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="1.487"
AnalystTargetPrice="2"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="57.83"
PriceToBookRatio="7.14"
EVToRevenue="32.87"
EVToEBITDA="-1.917"
Beta="1.451"
num_52WeekHigh="9.62"
num_52WeekLow="0.801"
num_50DayMovingAverage="3.151"
num_200DayMovingAverage="5.32"
SharesOutstanding="120507000"
DividendDate="None"
ExDividendDate="None"
symbol="MRSN"
open="1.21"
high="1.25"
low="1.17"
price="1.23"
volume="1775386.00"
latest_trading_day="2023-08-22"
previous_close="1.21"
change="0.02"
change_percent="1.6529%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="71"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Trending High"
value_analysis="Bullish Trend"
Aroon_change="FALSE"
Aroon_momentum="29"
Volume_recent_avg="5457005"
Change_recent_avg="0.05"
Delta_recent_avg="0.34"
Variance_recent_avg="0.17"
Change_ratio_recent_avg="1.0"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="29"
Aroon_momentum_negative="71"
image_negative_thumbnail_id_1="1104"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0137.jpeg"
image_negative_thumbnail_id_2="150"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0026.jpeg"
image_neutral_thumbnail_id_1="541"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0058.jpeg"
image_neutral_thumbnail_id_2="562"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0037.jpeg"
image_positive_thumbnail_id_1="966"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0128.jpeg"
image_positive_thumbnail_id_2="979"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0141.jpeg"
image_professor_thumbnail_id_1="1186"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0020.jpeg"
image_professor_thumbnail_id_2="1179"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0013.jpeg"
